ArticleInterdisciplinary sciences, computational life sciences2025
Identification of Multi-functional Therapeutic Peptides Based on Prototypical Supervised Contrastive Learning.
Article in Interdisciplinary sciences, computational life sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
5 citing papers in PubMed.
- PepPharmaHub: a cloud-based platform integrating multimodel language architectures with curated data resources for therapeutic peptide discovery.BMC biology · 2026Article
- Harnessing Machine Learning Approaches for the Identification, Characterization, and Optimization of Novel Antimicrobial Peptides.Antibiotics (Basel, Switzerland) · 2025Review
- METFAN: Multisource Enhanced Therapeutic Peptide Function Prediction via Adapter Network.ACS omega · 2025Article
- SeekTP: identifying multifunctional therapeutic peptides via graph attention and deep property integration.Briefings in bioinformatics · 2025Article
- AMCL: supervised contrastive learning with hard sample mining for multi-functional therapeutic peptide prediction.BMC biology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
High-throughput sequencing has exponentially increased peptide sequences, necessitating a computational method to identify multi-functional therapeutic peptides (MFTP) from their sequences. However, existing computational methods are challenged by class imbalance, particularly in learning effective sequence representations. To address this, we propose PSCFA, a prototypical supervised contrastive learning with a feature augmentation method for MFTP prediction. We employ a two-stage training scheme to train the feature extractor and the classifier respectively, underpinned by the principle that better feature representation boosts classification accuracy. In the first stage, we utilize a prototypical supervised contrastive learning strategy to enhance the uniformity of feature space distribution, ensuring that the characteristics of samples within the same category are tightly clustered while those from different categories are more dispersed. In the second stage, a feature augmentation strategy that focuses on infrequent labels (tail labels) is used to refine the learning process of the classifier. We use a prototype-based variational autoencoder to capture semantic links among common labels (head labels) and their prototypes. This knowledge is then transferred to tail labels, generating enhanced features for classifier training. The experiments prove that the PSCFA method significantly outperforms existing methods for MFTP prediction, making a significant advancement in therapeutic peptide identification.
Indexed as
Identifiers
39714581What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.